Use Self-Scheduling to book a primary care appointment online
Schedule now!
As of May 1, 2025, UK HealthCare will no longer be part of Cigna’s medical insurance network.
Cigna Q&A

Rina Plattner, PhD

  • Co-Leader, Molecular and Cellular Oncology Program
REQUEST AN APPOINTMENT

About

Faculty Rank

  • Professor

Research

Research Focus

Abl non-receptor tyrosine kinases, cancer invasion.

Programs

Molecular and Cellular Oncology

College & Department

Contact Information

209 Combs Building
University of Kentucky
Lexington, KY 40536
United States

Phone
859-323-4778
Email
rplat2@uky.edu

Publications

  1. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
    Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Cibull ML, Wang Ch, Novak M, Kaetzel, DM, Plattner R. Oncogene 31:1804-1816, 2012.
  2. Deregulated abl kinases promote proliferation, anchorage-independent growth and survival of aggressive breast cancer cells.
    Srinivasan D, Sims JT, Plattner R. Oncogene 27:1095-1105, 2008.
  3. SHP-2 is a novel target of Abl kinases during cell proliferation.
    Mitra S, Beach C, Feng GS, Plattner R. J Cell Sci 121:3335-3346, 2008.
  4. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κΒ and HSP27/p38/AKT pathways and by inhibiting ABCB1.
    Sims JT, Ganguly SS, Bennett H, Friend WJ, Tepe J, Plattner R. PLoS One 2013.